



GenesisTissue Inc.

GenesisTissue Inc. is pioneering 3D biofabrication of regenerative tissue implants for patients where traditional alloplastic implants fall short — or don't exist at all. Our first mission is bold and clear: to make silicone breast implants obsolete.



Company Overview

GenesisTissue Inc. is developing the future of breast surgery. Regenerative Breast Tissue (RBT) is a 3D bioprinted implantable scaffold that is made of a degradable material that is soft, feels like breast tissue, and mechanically supports an injected fat graft harvested from the patient's own body. RBT regenerates to become native tissue without risk of rejection, can be personalized to fit the defect, and is scalable to cosmetic breast surgery and many other soft tissues throughout the body.

All women deserve the ability to be reconstructed after breast cancer, the RBT solution will make a life-long reconstruction accessible to all breast cancer patients. GenesisTissue turns every breast surgeon into a plastic surgeon; one who can perform, bill, and get paid for inserting an RBT implant into their patients. RBT regenerates into native tissue and will not need to be replaced, reducing cost of care by decreasing complications and repeat surgeries. RBT is a safer alternative versus traditional silicone breast implants.

Problem

Breast implants are inadequate and outdated. There are 300,000 cosmetic breast and 160,000 breast reconstruction procedures per year in the US. 33% of reconstructions develop complications and 66,000 implants are removed yearly and increasing. Silicone implants have a limited lifespan and a 'black box' FDA warning due to complications from capsular contracture, migration, infection, and rupture. There are 200,000 lumpectomies per year and zero lumpectomy implants, limiting reconstruction options. Additionally, +20% of lumpectomies have positive cancer margins after tumor removal requiring re-excision.

Highlights

GenesisTissue is a spin out of 3D Systems, Inc. (NASDAQ: DDD) and was established as a mid-stage startup built on 4 years and \$8M in R&D (advanced biomaterials, high resolution bioprinters, and 6-month large animal data). Katie Weimer, MS, MBA (a 20-year leader in healthcare 3D printing), Evan Garfein, MD, MBA and Oren Tepper, MD (who are both world renowned plastic surgeons and leaders in healthcare technology development) led this projection at 3D Systems and are now developing this groundbreaking solution as co-founders of GenesisTissue.

2025 Goals: Strengthen financial position through Seed fundraising, grant applications, and monetizing unused tangible assets. Advancing Regenerative Breast Tissue and (second product) FATMESH™ to key research milestones. Initiate preparations for Series A round, targeting Q1 2026 kickoff.

Financial Info

Raising
\$2M

Location

Evergreen, CO 80439, USA

Business Stage
Seed

Business Type
Biotechnology

Meet the Team



Katie Weimer
CEO